IRVINE, Calif., May 17, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc. (“JenaValve or the “Company”), a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems , today announced the appointment of Kari Moore as the company’s Chief Financial Officer effective May 10, 2022.
“We are delighted to welcome Kari to the JenaValve team,” said JenaValve CEO John Kilcoyne.”Kari has over 35 years of extensive financial and operational experience in the medical device and healthcare industries. Kari’s extensive knowledge and industry expertise will help us continue to execute our clinical strategy and advance our Trilogy for the treatment of aortic valve disease ® Commercialization Efforts for Heart Valve Systems.”
Ms. Moore joins JenaValve after previously serving as Chief Accounting Officer for Envista Holdings Corporation, a global dental products company, where she was responsible for global accounting, finance and shared services functions.Prior to joining Envista Holdings Corporation, Ms. Moore was the Chief Accounting Officer of Applied Medical Corporation, a global medical device company providing technologies and solutions for minimally invasive and general surgery.Ms. Moore began her operations at PricewaterhouseCoopers, where she worked as an audit partner, specializing in the life sciences industry.During her 20-year career, Ms. Moore has taken many companies public and assisted them in acquisitions, divestitures and debt issuances.Kari holds a BA in Business Administration from the University of Southern California and is a CPA in the state of California.
“I am delighted to be joining JenaValve at such a critical time,” said Ms. Moore. “I am excited to work with the entire JenaValve team as we continue to execute on our growth and value creation strategies while improving the lives of patients.”
About JenaValve JenaValve Technology, Inc., headquartered in Irvine, California, with locations in Leeds, UK and Munich, Germany, develops and manufactures transcatheter aortic valve replacement (TAVR) systems for the treatment of patients with aortic valve disease.JenaValve is backed by Bain Capital Life Sciences and Cormorant Asset Management, as well as European and Asian investors including Andera Partners, Gimv (Euronext: GIMB), Legend Capital, NeoMed Management, RMM, Valiance Life Sciences, VI Partners and Peijia Medical Limited (HKEx: 9996).
United States: Attention – Research Equipment.Restricted by federal (or U.S.) law for research use only.
Post time: May-18-2022
